CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways

BACKGROUND: Malignant gliomas are associated with a high mortality rate, and effective treatment options are limited. Thus, the development of novel targeted treatments to battle this deadly disease is imperative. METHODS: In this study, we investigated the in vitro effects of the novel reversible c...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xuejiao, Chong, Yulong, Tu, Yiming, Liu, Ning, Yue, Chenglong, Qi, Zhenglei, Liu, Huize, Yao, Yao, Liu, Hongmei, Gao, Shangfeng, Niu, Mingshan, Yu, Rutong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059893/
https://www.ncbi.nlm.nih.gov/pubmed/27733172
http://dx.doi.org/10.1186/s13045-016-0338-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059893/
https://www.ncbi.nlm.nih.gov/pubmed/27733172
http://dx.doi.org/10.1186/s13045-016-0338-2

Ejemplares similares